Graft versus host disease (GvHD) is a complication from stem cell transplants where the patient recognises the cells as ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

In this interview, News Medical speaks with Olivier Negre, Chief Scientific Officer at Smart Immune, about how immunotherapy is being revolutionized.

In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...

| Is immunotherapy the future of cancer treatment? In the latest episode of Podnosis, Dr. Steven O’Day of Agenus discusses ...

“Elovl1-deficient T cells present increased mitochondrial fitness and fatty ... This research underscores the potential of metabolic engineering in immunotherapy, paving the way for innovative ...

Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T ...

Researchers have discovered a new approach to prostate cancer treatment by combining immunotherapy with PIM1 kinase ...

Agenus Chief Medical Officer Dr. Steven O'Day joined Fierce's Chris Hayden on a recent sponsored episode of The Top Line ...

This cancer-patient dad of three young kids is grateful for a "sci-fi" blood treatment advanced by Vanderbilt and oncologist Dr. Olalekan Oluwole.

Protheragen is an advanced CAR-T cell therapy service provider. With its extensive experience in cell therapy development and ...